[Zaditen: a pharmacologic and therapeutic profile].
The pharmacological properties of Zaditen include the inhibition of mediator release, the inhibition of bronchial hyperreactivity and the suppression of beta-adrenergic tachyphylaxis. Its therapeutic efficacy is characterized by a reduction of the severity and the variability of asthma combined with a decrease of bronchodilator use and a progressive improvement of pulmonary function. The normalization of physical activities and sleep disturbances, less absenteeism at work or school, witness a better quality of life. Long term safety and tolerance are excellent.
Craps
L P
LP
Division pharmaceutique, Sandoz S.A., Bâle, Suisse.
D001249:Asthma / Q000188:drug therapy; D006636:Histamine Release / Q000187:drug effects; D006801:Humans; D007665:Ketotifen / Q000494:pharmacology* / Q000627:therapeutic use*
D007665:Ketotifen
Le Zaditen: un profil pharmacologique et thérapeutique.